AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01889992 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac MRI
Description: 1 month post HTx, year 1 and year 2 annual post HTx eval. CMRIs completed using 1.5-Tesla Whole Body MRI system. Scout images will determine short \& long-axis views of the heart. ECG-gated cine MR of 3 long axis and a contiguous short axis orientation will be obtained. T1-weighted delayed enhancement images will be obtained 10 minutes after injection of a gadolinium-based contrast agent. Measurements from each slice will be summed using the method of disks. Myocardial mass will be estimated by multiplying the myocardial wall volume at end diastole by the specific gravity of muscle (1.05gm/ml) and LV hypertrophy will be defined as LV mass indexed to height in meters 2.7 >/=35.8 g/m 2.7) (18). Delayed Gadolinium enhancement will be defined as any enhancement pattern greater than 0%.
Study NCT01889992 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Cardiac MRI
Description: 1 month post HTx, year 1 and year 2 annual post HTx eval. CMRIs completed using 1.5-Tesla Whole Body MRI system. Scout images will determine short \& long-axis views of the heart. ECG-gated cine MR of 3 long axis and a contiguous short axis orientation will be obtained. T1-weighted delayed enhancement images will be obtained 10 minutes after injection of a gadolinium-based contrast agent. Measurements from each slice will be summed using the method of disks. Myocardial mass will be estimated by multiplying the myocardial wall volume at end diastole by the specific gravity of muscle (1.05gm/ml) and LV hypertrophy will be defined as LV mass indexed to height in meters 2.7 >/=35.8 g/m 2.7) (18). Delayed Gadolinium enhancement will be defined as any enhancement pattern greater than 0%.
Study NCT01889992 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary angiography with IVUS
Description: Coronary angiography is a test that uses dye and special x rays to show the insides of your coronary arteries. The coronary arteries supply oxygen-rich blood to your heart.~Intravascular ultrasound is a test that uses sound waves to see inside blood vessels. This article discusses intravascular ultrasound to see inside the coronary arteries, the blood vessels that supply the heart.
Study NCT01889992 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronary angiography with IVUS
Description: Coronary angiography is a test that uses dye and special x rays to show the insides of your coronary arteries. The coronary arteries supply oxygen-rich blood to your heart.~Intravascular ultrasound is a test that uses sound waves to see inside blood vessels. This article discusses intravascular ultrasound to see inside the coronary arteries, the blood vessels that supply the heart.
Study NCT04306705 — intervention group
Intervention type: PROCEDURE
Intervention: Continuous renal replacement therapy
Description: Catheter insertion site is femoral vein.
Study NCT03278769 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lung protective ventilator settings
Description: Positive end-expiratory pressure 12, Tidal volume 6 milliliter/kilogram predicted body weight
Study NCT01889992 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiac Allograft Remodeling
Description: A surgical procedure in which a diseased heart is replaced with a healthy heart from a deceased person.
Study NCT01889992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M-TOR Immunosuppression
Description: Sirolimus (INN/USAN), also known as rapamycin, is an immunosuppressant drug used to prevent rejection in organ transplantation; it is especially useful in kidney transplants. It prevents activation of T cells and B-cells by inhibiting their response to interleukin-2 (IL-2).~Sirolimus dosage based on blood levels.
Study NCT01889992 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac Biopsy C4D stain
Description: A long, thin tube called a biopsy catheter is inserted through a vein in your neck or grion and guided through your blood vessels to your heart.
Study NCT01889992 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genetic Mechanism of M-TOR
Description: To identify the molecular and genetic mechanisms associated with development of early post-transplant CAR, and to evaluate the impact of mTOR-inhibitor Sirolimus on this process.
Study NCT01889992 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cardiopulmonary Exercise Test (CPET)
Description: The Cardiopulmonary Exercise Test is a highly sensitive, non-invasive stress test. It is considered a stress test because the exercise stresses your body's systems by making them work faster and harder. A disease or condition that affects the heart, lungs or muscles will limit how much faster and harder these systems can work. A CPET assesses how well the heart, lungs, and muscles are working individually, and how these systems are working in unison. Your heart and lungs work together to deliver oxygen to your muscles, where it is used to make energy, and to remove carbon dioxide from your body.
Study NCT02969070 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: LopiGLIK™ therapy
Description: 4 weeks of LopiGLIK™ therapy 1 capsule/day
Study NCT02969070 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Armolipid Plus® therapy
Description: 4 weeks of Armolipid Plus® therapy 1 capsule/day
Study NCT03669796 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Marine protein hydrolysate (mph)
Description: Marine (Cod) protein hydrolysate
Study NCT03669796 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Maltodextrin/Casein
Study NCT04554303 — intervention group
Intervention type: DRUG
Intervention: S-amlodipine 2.5mg
Description: Oral administration, 1 tablet per day
Study NCT02606448 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Ropivicaine was used in all femoral nerve blocks
Study NCT04554303 — intervention group
Intervention type: DRUG
Intervention: Amlodipine 5mg
Description: Oral administration, 1 tablet per day
Study NCT01854684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temoporfin
Description: Given IV
Study NCT01854684 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgical resection
Study NCT01854684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Photodynamic Therapy
Description: Undergo intraoperative PDT
Study NCT01854684 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02092441 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol prep pad group
Description: Subjects inhale scent of alcohol pad
Study NCT02092441 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline prep pad
Description: Subjects inhale scent of placebo (normal saline) pads
Study NCT02156492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evacetrapib
Description: Administered orally.
Study NCT01854684 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT04047446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel 133 MG Per 10 ML Injection
Description: 10mL of 133mg liposomal bupivacaine with 5mL of 0.5% bupivacaine (15mL total)
Study NCT04047446 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 15mL of 0.5% bupivacaine with 4mg of preservative-free dexamethasone will be injected
Study NCT04156139 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HFNC
Description: The gas flow rate was set at 45\~55 L/min. The inhaled oxygen concentration will be dynamically adjusted to maintain SpO2 ≥ 92%. The temperature will be set at 37 °C.
Study NCT04156139 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HFNC
Description: The gas flow rate was set at 45\~55 L/min. The inhaled oxygen concentration will be dynamically adjusted to maintain SpO2 ≥ 92%. The temperature will be set at 37 °C.
Study NCT04156139 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NPPV
Description: The PEEP is initially set as 5 cm H2O, the inspiratory pressure is 10 cm H2O, and the target tidal volume is 6-8 ml/kg.
Study NCT04156139 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NPPV
Description: The PEEP is initially set as 5 cm H2O, the inspiratory pressure is 10 cm H2O, and the target tidal volume is 6-8 ml/kg.
Study NCT01020357 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine citrate injection
Description: Loading dose: 20 mg/kg administered over at least 30 minutes via IV infusion or over at least 10 minutes via slow IV injection.~Daily maintenance dose (to commence at least 24 hours after loading dose): 5 mg/kg, administered over at least 10 minutes via IV infusion, or over at least 5 minutes via slow IV injection. Maintenance dose to be adjusted for body weight every 7 days. If indicated, maintenance dose may be increased to a maximum of 10 mg/kg. May be given orally once full enteral feeds are established.~Duration of treatment: discontinue after infant has tolerated at least 5 consecutive days without positive pressure support AND when the infant is judged by the attending clinician to be no longer a candidate for methylxanthine therapy.
Study NCT01020357 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: normal saline
Study NCT03515421 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Frazier 3 Verio
Description: In vitro diagnostic device (IVDD)
Study NCT03515421 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Frazier 3 UltraPlus
Description: In vitro diagnostic device (IVDD)
Study NCT00757068 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT addressing postpartum mood and weight concerns
Description: Women will be assigned an individual counselor who will meet with them face-to-face six times and telephone them seven times. In these treatment sessions, the counselor will address postpartum mood and weight concerns.
Study NCT00757068 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Behavioral Therapy
Description: Women will be assigned an individual counselor who will meet with them face-to-face six times and telephone them seven times. A non-specific, supportive condition will be delivered to women who want to remain smoke-free after they give birth.
Study NCT02560649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a plus Entecavir
Description: Peginterferon alfa-2a 180μg /wk plus Entecavir 0.5mg qd for 48 weeks(Arm A and B)
Study NCT02560649 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon alfa-2a plus Entecavir
Description: Peginterferon alfa-2a 180μg /wk plus Entecavir 0.5mg qd for 48 weeks(Arm A and B)
Study NCT04322318 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo a biopsy
Study NCT04322318 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT04322318 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo a bone scan
Study NCT04322318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT04322318 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo a CT scan
Study NCT04322318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT04322318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV
Study NCT04322318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study NCT04322318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Given IV
Study NCT04322318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Given IV
Study NCT04322318 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT04322318 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo a PET scan
Study NCT04322318 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo RT
Study NCT04322318 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Procedure
Description: Undergo surgery
Study NCT04322318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: Given IV
Study NCT04322318 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transabdominal Ultrasound
Description: Undergo abdominal ultrasound
Study NCT04322318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV
Study NCT04322318 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo a chest x-ray
Study NCT01178840 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: WC then FC2
Description: 4 uses of WC followed by 4 uses of FC2
Study NCT01178840 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: FC2 then WC
Description: 4 uses of WC followed by 4 uses of FC2
Study NCT04347421 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Krill oil group
Description: This group takes 500 mg/day Krill oil for 12 weeks.
Study NCT04347421 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: This group takes 500 mg/day Placebo for 12 weeks.
Study NCT03004885 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PrismaLung
Description: Low flow Extracorporeal CO2 removal using a 0.32 m² membrane oxygenator
Study NCT02560649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a plus Lamivudine
Description: Peginterferon alfa-2a 180μg /wk plus Lamivudine 0.1g qd for 48 weeks(Arm A and B)
Study NCT02560649 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon alfa-2a plus Lamivudine
Description: Peginterferon alfa-2a 180μg /wk plus Lamivudine 0.1g qd for 48 weeks(Arm A and B)
Study NCT02560649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a plus Adefovir
Description: Peginterferon alfa-2a 180μg /wk plus Adefovir 10mg qd for 48 weeks(Arm A and B)
Study NCT03004885 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PrismaLung
Description: Low flow Extracorporeal CO2 removal using a 0.32 m² membrane oxygenator
Study NCT01078948 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation (tDCS)
Description: Delivery of mild current to specified brain regions.
Study NCT01078948 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulation (tDCS)
Description: Delivery of mild current to specified brain regions.
Study NCT02295462 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Person-centered Care
Description: Medication Review + Person-centered Care
Study NCT02295462 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Optimised Treatment
Description: Medication Review only
Study NCT02295462 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optimised Treatment
Description: Medication Review only
Study NCT02560649 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon alfa-2a plus Adefovir
Description: Peginterferon alfa-2a 180μg /wk plus Adefovir 10mg qd for 48 weeks(Arm A and B)
Study NCT02560649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a plus Tenofovir
Description: Peginterferon alfa-2a 180μg /wk plus Tenofovir 300mg qd for 48 weeks(Arm A and B)
Study NCT02560649 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon alfa-2a plus Tenofovir
Description: Peginterferon alfa-2a 180μg /wk plus Tenofovir 300mg qd for 48 weeks(Arm A and B)
Study NCT02560649 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir
Description: Entecavir 0.5mg qd for 24 weeks(Arm C)
Study NCT03667105 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CAF
Description: Periodontal surgical technique to treat gingival recessions.
Study NCT03667105 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CAF
Description: Periodontal surgical technique to treat gingival recessions.
Study NCT03667105 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MC
Description: Xenogenous graft placed in the surgical site.
Study NCT03667105 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: XDM
Description: Xenogenous dermal collagen graft placed in the surgical site.
Study NCT02560649 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamivudine
Description: Lamivudine 0.1g qd for 24 weeks(Arm C)
Study NCT02560649 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adefovir
Description: Adefovir 10mg qd for 24 weeks(ArmC)
Study NCT02560649 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir disoproxil
Description: Tenofovir 300mg qd for 24 weeks(Arm C)
Study NCT01426269 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: During phase 1 (baseline - week 12): Oracea (doxycycline 40 mg USP (30 mg immediate release \& 10 mg delayed release beads)), oral, one capsule daily in the morning During phase 1 (baseline - week 12) and phase 2 (week 12 - week 52): Oracea (doxycycline 40 mg USP (30 mg immediate release \& 10 mg delayed release beads), oral, one capsule daily in the morning
Study NCT01426269 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Doxycycline
Description: During phase 1 (baseline - week 12): Oracea (doxycycline 40 mg USP (30 mg immediate release \& 10 mg delayed release beads)), oral, one capsule daily in the morning During phase 1 (baseline - week 12) and phase 2 (week 12 - week 52): Oracea (doxycycline 40 mg USP (30 mg immediate release \& 10 mg delayed release beads), oral, one capsule daily in the morning
Study NCT01426269 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Metronidazole
Description: During Phase 1: MetroGel 1% (metronidazole 1% gel), topical, apply a thin layer once daily to the affected area
Study NCT01426269 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: During phase 2 (week 12 - week 52): placebo, oral, one capsule daily in the morning
Study NCT00596609 — intervention group
Intervention type: DRUG
Intervention: Intrathecal Morphine
Description: * In the IT morphine group, prior to IT morphine injection (within 15 minutes of the injection), the neurophysiologist will be asked to obtain a set of TceMEP recordings. The recordings collected at this time will be labeled Baseline. These will serve as controls for subsequent recording comparisons.~* In the IT morphine group, the time of IT morphine injection will be recorded, as well as the dose. A timer will be started. The neurophysiologist will then be asked to collect four additional sets of TceMEP recordings, at 5, 10, 20, and 30 minutes after morphine injection.
Study NCT00492271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Friulimicin B
Description: Intravenous, once daily, single dose
Study NCT03426033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 681257
Description: Xmg dose administered as a subcutaneous injection
Study NCT03426033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: 25mg tablet administered orally
Study NCT03731377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crystalloid Solutions
Description: Mini-fluid challenge with crystalloid 250 ml will be given to patients first. After observation of hemodynamic parameters, further fluid challenge will be given for response observation.
Study NCT01763086 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cells
Description: Mesenchymal stem cells will be intravenously infused via a central venous catheter,at a dose of 1×10\^6 cells/kg, over 15 min. The vital signs of all patients will be closely monitored during and for 24h after MSCs administration. If the NEU and PLT levels do not attain the completely response(CR)standards within 14d, a second course of MSCs treatment will be given.
Study NCT02759588 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GL-ONC1 alone, or in combination with chemotherapy with or without bevacizumab
Description: GL-ONC1 is a genetically-engineered oncolytic vaccinia virus, which is administered via intraperitoneal infusion as multiple doses.
Study NCT00414544 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CosmetaLife
Description: Dermal filler
Study NCT00414544 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Restylane
Description: Dermal filler
Study NCT00549848 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone, Vincristine, Daunorubicin, PEG-L-asparaginase, Erwinia L-asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Thioguanine
Description: See Detailed Description section for details of treatment interventions.
Study NCT00549848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone, Vincristine, Daunorubicin, PEG-L-asparaginase, Erwinia L-asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Thioguanine
Description: See Detailed Description section for details of treatment interventions.